Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc.
Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. in Plant Molecular Genetics from Seoul National University, and a B.S. in Horticultural Science from Seoul National University.
Mr. Bakshi earned a B.S. in biochemistry and Cell Biology from the University of California, San Diego and a M.S. in Biotechnology from University of Queensland, Australia.
Dr. Bartynski earned a B.S. in Chemical Engineering from Lehigh University and his Ph.D. in Chemical Engineering from the University of Southern California.
Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany.
Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany.